Conjugated Estrogens
Conjugated estrogens are a mixture of estrogen sulfates derived from pregnant mare urine, used in postmenopausal hormone replacement therapy. Available as oral tablets and topical formulations, marketed primarily as Premarin.
- CAS number
- 12126-59-9
- ATC code
- G03CA57
- Molecular weight
- 265-272 g/mol (mixture)
- Drug class
- Hormone replacement therapy (estrogen mixture)
- Also known as
- CE, Premarin
What is it?
Conjugated estrogens are a mixture of naturally-derived estrogen sulfate esters, originally extracted from pregnant mare urine. The molecule has been used in clinical practice since the 1940s under the brand name Premarin (manufactured by Wyeth, now Pfizer) and is one of the longest-established hormone replacement therapy options for postmenopausal women. The mixture contains primarily estrone sulfate (about 50%), equilin sulfate (about 25%), and smaller amounts of other estrogen sulfates. Synthetic conjugated estrogens and authorised generics offer alternatives.
Mechanism of action
Conjugated estrogens act on estrogen receptors throughout the body, restoring estrogen signalling lost after menopause. In hormone replacement therapy, they primarily address vasomotor symptoms (hot flashes, night sweats) and genitourinary syndrome of menopause (vaginal atrophy, urinary symptoms). They also slow postmenopausal bone loss and reduce osteoporotic fracture risk. According to the prescribing information, the addition of a progestogen is required in women with intact uterus to prevent estrogen-driven endometrial hyperplasia.
Pharmacokinetics
After oral administration, conjugated estrogens are partially hydrolysed in the gut to active estrogens (primarily estrone), which are then absorbed and partially conjugated again in the liver. The complex pharmacokinetics involves enterohepatic recirculation. Steady-state plasma concentrations of estrone are reached within several days of regular daily dosing. Hepatic metabolism via CYP3A4 produces a range of active and inactive metabolites. Excretion is primarily through urine and faeces.
Indications
Conjugated estrogens are approved for moderate to severe vasomotor symptoms of menopause, vulvovaginal atrophy due to menopause, osteoporosis prevention in postmenopausal women at significant risk, and primary ovarian failure or female hypogonadism. The combination with a progestogen is required in women with intact uterus. According to current guidelines, hormone therapy is best initiated within 10 years of menopause and before age 60, when the risk-benefit profile is most favourable.
Safety profile
Common adverse effects include nausea, breast tenderness, fluid retention, headache and breakthrough bleeding. The most clinically important risks are increased venous thromboembolism (especially with oral routes), increased breast cancer risk with long-term combined therapy, and a small increase in stroke risk. Endometrial hyperplasia and cancer risk is markedly increased without concurrent progestogen in women with uterus. Cardiovascular benefit observed in observational studies has not been confirmed in randomised trials and may depend on age and time since menopause.
Products containing this ingredient
Frequently asked questions
What are conjugated estrogens made from? ▾
The original Premarin contains conjugated estrogens extracted from pregnant mare urine — the brand name combines 'PRE'gnant 'MAR'es' urI'N'e. The mixture includes naturally occurring estrogen sulfates, primarily estrone sulfate, equilin sulfate and several minor estrogens. Synthetic alternatives and generics offer plant-derived or chemically synthesised mixtures matching the originator's composition profile. According to the prescribing information, all forms produce comparable estrogen receptor activation when dosed equivalently.
When should hormone replacement therapy be started? ▾
According to current guidelines, hormone replacement therapy initiated within 10 years of menopause and before age 60 has the most favourable risk-benefit profile in symptomatic women. Initiation more than 10 years after menopause or after age 60 is associated with greater cardiovascular and thromboembolic risk and is generally avoided. Decisions should be individualised based on symptom severity, personal/family history of breast cancer or thrombosis, and preferences.
Do I need a progestogen with conjugated estrogens? ▾
Women with an intact uterus require concurrent progestogen therapy to prevent estrogen-driven endometrial hyperplasia and cancer. Progestogen can be given continuously (daily) or cyclically (12-14 days per month). Women without a uterus (after hysterectomy) generally do not require progestogen. According to the prescribing information, omitting progestogen in women with uterus increases endometrial cancer risk substantially, with no benefit to compensate.
What is the difference between Premarin and generic conjugated estrogens? ▾
Premarin is the original Pfizer brand of conjugated estrogens derived from pregnant mare urine. Authorised generic conjugated estrogens contain the same molecule mixture and meet the same regulatory bioequivalence requirements; differences include manufacturer, source (some generics use synthetic estrogens), excipients and price. According to clinical guidelines, an authorised generic is an acceptable substitute for Premarin in most women.
Are there alternatives to conjugated estrogens for menopausal symptoms? ▾
Alternative estrogens used in HRT include estradiol (oral, transdermal, vaginal), and lower-dose vaginal estrogens for genitourinary symptoms only. Non-hormonal options for vasomotor symptoms include certain antidepressants (paroxetine, venlafaxine), gabapentin, and lifestyle measures. According to current guidelines, transdermal estrogens have a lower thromboembolic risk than oral estrogens and may be preferred in some patients.
The information on this website is provided for reference and educational purposes only. It does not replace consultation with a qualified healthcare professional.